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Abstract
The causes of poor clinic attendance and incomplete virologic suppression among HIV+ African Americans
(AAs) are not well understood. We estimated the effect of at-risk alcohol/drug use and associated treatment on
attending scheduled appointments and virologic suppression among 576 HIV + AA patients in the University of
Alabama at Birmingham (UAB) 1917 Clinic Cohort who contributed 591 interviews to the analysis. At interview,
78% of patients were new to HIV care at UAB, 38% engaged in at-risk alcohol/drug use or received associated
treatment in the prior year, while the median (quartiles) age and CD4 count were 36 (28; 46) years and 321 (142;
530) cells/ll, respectively. In the 2 years after an interview, half of the patients had attended at least 82% of
appointments while half had achieved virologic suppression for at least 71% of RNA assessments. Compared to
patients who did not use or receive treatment, the adjusted risk ratio (aRR) for attending appointments for patients
who did use but did not receive treatment was 0.97 (95% confidence limits: 0.92, 1.03). The corresponding aRR
for virologic suppression was 0.94 (0.86, 1.03). Compared to patients who did not receive treatment but did use,
the aRR for attending appointments for patients who did receive treatment and did use was 0.86 (0.78, 0.95). The
corresponding aRR for virologic suppression was 1.07 (0.92, 1.24). Use was negatively associated with attendance
and virologic suppression among patients not in treatment. Among users, treatment was negatively associated with
attendance yet positively associated with virologic suppression. However, aRR estimates were imprecise.
Introduction
In 2009, African Americans (AAs) accounted for 12% ofthe United States population. However, compared to other
racial and ethnic groups, AAs continue to be overrepresented
among cases of adverse HIV-related outcomes at all stages of
HIV disease.1 Specifically, AAs are more likely than non-
AAs to become HIV infected2 and suffer disproportionally
from poor HIV-related outcomes, including virologic fail-
ure3,4 and death.2,5 Reduced access to and use of medical
services have been indicated as key determinants of racial
disparities in HIV-related morbidity and mortality.5,6
Among patients in HIV care, AAs are more likely than
whites to miss scheduled clinic appointments.4,7–9 Missing
scheduled clinic appointments may be a marker of reduced
access to and engagement in care and has been linked to a
greater burden of virologic failure,4,10,14 AIDS-defining ill-
nesses,15 and death.16–18 Mugavero et al.4 demonstrated that
the proportion of scheduled appointments that were missed
partially explained why AAs were less likely to suppress
plasma HIV-1 RNA levels while on antiretroviral therapy
(ART) compared to whites in the University of Alabama at
Birmingham (UAB) 1917 Clinic Cohort.
The link between missed scheduled clinic appointments
and poor HIV-related outcomes may be due to lower receipt
and less timely modification of as well as nonadherence to
ARTs among those who frequently miss scheduled appoint-
ments.4 However, the reasons for less frequent scheduled
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clinic attendance among AAs are not well characterized.
Guided by the Anderson19 and Messeri20 models for health
services access and use as well as observed lower use or
completion of abuse treatment services among AAs com-
pared to whites, drug and alcohol use may play a role in racial
disparities in clinic attendance.21,22 To add to the limited, but
critical literature on alcohol/drug use, scheduled appointment
attendance, and HIV virologic responses among AAs, we
used data on 576 AA patients in the UAB 1917 Clinic Cohort
to estimate the effect of at-risk alcohol/drug use and associ-
ated treatment on attending scheduled clinic appointments
and achieving virologic suppression.
Materials and Methods
Study population
The UAB 1917 Clinic Cohort is an HIV clinical cohort
established in 1992 that collects sociodemographic, psycho-
social, and clinical information from all patients who receive
care at the UAB 1917 HIV/AIDS Clinic. The UAB institu-
tional review board approved all study forms and protocols.
Relevant patient information was obtained from medical re-
cords and an administered interview introduced in January
2007. Additional details regarding data collection for this
clinic cohort are provided elsewhere.23
Of the 892 new or returning (after more than 12 months out
of care) AA patients who were seen and completed an inter-
view at the UAB 1917 HIV/AIDS clinic between January 1,
2007 and July 29, 2012, five patients were excluded from the
analysis due to the absence of information on one or more
characteristics at the first clinic visit. An additional 166 pa-
tients were excluded due to the inclusion of a nonresponse
(i.e., no answer) for information on alcohol/drug use or
treatment in the prior year at the time of their interview.
Another 145 patients were excluded due to the absence of
information on relevant characteristics at the interview or on
either of the outcomes in the 2 years after the interview.
Assessment of alcohol/drug use and treatment
as well as other patient characteristics
Both the effect of at-risk alcohol/drug use and treatment
for use in the year prior to an administered interview were
examined. Specifically, the effect of use in the last year
among those who did and did not receive treatment in the
same time period was examined. In addition, the effect of
treatment in the last year among those who did and did not use
in the same time period was assessed.
At-risk alcohol/drug use in the year prior to an adminis-
tered interview was obtained from patient medical records
and self-reports during the interview. A patient was consid-
ered to have engaged in at-risk alcohol use if an alcohol-
related diagnosis appeared in their medical record or if they
reported behavior consistent with ‘‘at-risk alcohol use’’ as
defined by the Alcohol Use Disorders Identification Test-
Consumption [AUDIT-C] instrument24 in the year prior to
their interview. A patient was considered to have used drugs
if a drug-related diagnosis appeared in their medical record in
the year prior to their interview or if they reported at inter-
view any use during the preceding 3 months of injection
drugs, crack/cocaine, amphetamines, or opioids that were not
prescribed by a physician. Marijuana use was excluded to be
consistent with prior work.25 Patients who did not have an
alcohol or drug-related diagnosis in the year prior to an in-
terview and did not report (or meet the criterion for) use at an
interview were considered to not have engaged in at-risk
alcohol/drug use in the year prior to the interview.
Treatment for alcohol or drugs in the year prior to an ad-
ministered interview was obtained from patient medical re-
cords and self-reports during the interview. A patient was
considered to have received treatment for alcohol or drugs if
the medical record documented the patient’s attendance at an
alcohol or drug abuse counseling appointment or a patient re-
ported receiving treatment for alcohol or drugs in the year prior
to an interview. Patients without an attended alcohol or drug
abuse counseling appointment included in their medical record
in the year prior to an interview and who did not report treat-
ment receipt in the prior year at an interview were considered to
have not received alcohol or drug use treatment in the year prior
to an interview. Information on characteristics such as calendar
dates, age, sex, clinical AIDS diagnoses, CD4 cell count, ART
history, education, insurance status, long-term alcohol/drug
use, and mental health history (i.e., diagnoses, self-reported
symptoms, and treatment) were also obtained from patient
medical records or self-reports during an interview.
Ascertainment of scheduled appointment
attendance and virologic suppression
The two primary outcomes of interest in this analysis were
attendance of a scheduled appointment and achieving viro-
logic suppression at a given HIV-1 RNA assessment during the
2 years following an administered interview. A 2-year post-
interview window was selected to assess more recent effects of
use and treatment while ensuring a sufficient amount of time
for multiple scheduled appointments and RNA assessments.
The primary outcomes corresponded to all scheduled
clinic appointments with a primary HIV provider and RNA
assessments that occurred in the 2-year period after an ad-
ministered interview between January 1, 2007 and July 29,
2012. As done previously,4,18 scheduled appointments that
were canceled or rescheduled by the patient or provider were
excluded from the analysis as well as scheduled urgent care
or subspecialty appointments (e.g., dermatology). Walk-in
visits were also excluded from the definition of a scheduled
appointment given that all patients who walked in were as-
signed an urgent care appointment.
To harmonize HIV-1 RNA data across time, all RNA
values < 400 copies/ml were set to 200 copies/ml and re-
garded as undetectable. Virologic suppression was defined as
achieving an undetectable plasma HIV-RNA (e.g., £ 200
copies/ml) at a given RNA level assessment. Patients were
not required to have initiated ART by a given RNA level
assessment. Patients not observed for any period of more than
1 year during the 2 years subsequent to an interview were
censored at the minimum of their death date (if applicable)
and 1 year after the date of their last contact with the HIV/
AIDS clinic. Patients who were known to be alive and had
their last contact with the clinic within the 2 years after an
interview as well as within a year of July 29, 2012 or within
the second year after an interview were administratively
censored at the minimum of July 29, 2012 and 2 years after an
interview. Patients observed to be alive and had their last
contact with the clinic beyond 2 years after an interview and
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more than a year before July 29, 2012 were administratively
censored at 2 years subsequent to an interview.
Statistical analysis
Characteristics of included and excluded patients were ex-
amined and compared based on percentages for discrete
characteristics or medians and quartiles for continuous char-
acteristics. Unadjusted and adjusted modified Poisson regres-
sion models26 were used to estimate risk ratios (RRs) for the
effect of at-risk alcohol/drug use and associated treatment on
scheduled appointment attendance and virologic suppression
where the time scale was years since the last attended sched-
uled appointment (or years since the last virologic suppres-
sion). An indicator of at-risk alcohol/drug use, an indicator of
alcohol/drug treatment, and the product term of these two in-
dicators were included in all unadjusted and adjusted models.
Based on prior literature20 a product term was included to
allow for potential effect measure modification of the effect of
use by treatment and vice versa. The outcome in these models
was either an indicator of whether a patient attended a given
scheduled appointment or an indicator of whether a patient
achieved virologic suppression during a plasma HIV-1 RNA
assessment in the 2 years after an interview. An independent
working correlation structure was specified for the modified
Poisson regression models.
Models were adjusted for age, calendar date, gender, an
AIDS diagnosis, and CD4 cell count at first clinic visit as well
as time since first clinic visit in addition to CD4 cell count,
time on ART, highest education level attained, insurance,
history of mental health issues and/or treatment, and long-
term drug/alcohol use at interview. The first clinic visit was
defined as the minimum of the first primary HIV provider
visit and the first interview between January 1, 1995 and July
29, 2012. Adjustment for long-term alcohol and drug use
excluded use history in the year prior to an interview.
Adjustment was used to correct for bias due to confounding
as well as selection bias potentially induced by analysis sample
restrictions, pattern of clinic attendance, and censoring due to
dropout or death.27–29 Predictors in all models were included
as either indicator variables for categories or restricted qua-
dratic splines with knots at the 5, 35, 65, and 95th percentiles30
for continuous characteristics. All analyses were conducted
using SAS version 9.3 (SAS Institute, Cary, NC).
Results
Among the 576 patients in the UAB 1917 Clinic Cohort
that were included in the analysis and followed for 932 per-
son-years after an interview, as of July 29, 2012, 47 dropped
out, 6 died, and 523 were alive and under follow-up 2 years
after their interview. These patients contributed 591 inter-
views to the analysis. Table 1 shows the characteristics of the
591 included interviews along with characteristics of those
patients that were excluded from the analysis due to lack of
information after the first clinic visit.
Among the 591 included interviews, 78% of patients were
new to HIV care at UAB at the time of their interview. Se-
venty-five percent of interviews were contributed by men
and 33% were contributed by patients who previously had
received a clinical AIDS diagnosis at the time of their first
clinic visit. The median (quartiles) age and CD4 count at the
first clinic visit were 34 (27; 44) years and 331 (147; 529)
cells/ll, respectively. Thirty-eight percent of interviews were
contributed by a patient who engaged in at-risk alcohol/drug
use or had received alcohol or drug treatment in the year prior
to an interview.
The median number of scheduled appointments within the 2
years after an interview was 7 (4; 9), while the median number
of HIV-1 RNA measures taken within the 2 years after an
interview was 4 (2; 6). The median proportion of scheduled
appointments attended within the 2 years after an interview
was 0.82 (0.67; 1), while the median proportion of HIV-1 RNA
measures taken within the 2 years after an interview that
achieved virologic suppression was 0.71 (0.33; 1). Compared
to patients who were excluded from the analysis due to a
nonresponse about alcohol/drug use or treatment, patients who
were included tended to have a later first clinic visit calendar
date as well as be younger and have less advanced HIV disease
at the first clinic visit. Included patients also tended to have a
later first clinic visit calendar date yet have more advanced
HIV disease at the first clinic visit than patients excluded from
the analysis due to a lack of information on characteristics at
interview or on the outcomes.
Table 2 provides the unadjusted and adjusted association
between at-risk alcohol/drug use and scheduled appointment
attendance among those who did and did not receive alcohol
and drug treatment. Compared to patients who did not use but
did receive treatment in the prior year, the unadjusted RR for
attending scheduled appointments after an interview for pa-
tients who did use and did receive treatment was 0.85 (95%
confidence limits: 0.72, 0.99). Compared to patients who did
not use and did not receive treatment in the prior year, the
unadjusted RR for attending scheduled appointments after an
interview for patients who did use, but did not receive
treatment was 0.94 (0.90, 0.99). The corresponding adjusted
RRs for attending scheduled appointments after an interview
were 0.89 (0.77, 1.04) and 0.97 (0.92, 1.03), respectively.
Table 3 shows the unadjusted and adjusted association be-
tween at-risk alcohol/drug use and virologic suppression
among those who did and did not receive alcohol and drug
treatment. Compared to patients who did not use but did re-
ceive treatment in the prior year, the unadjusted RR for viro-
logic suppression after an interview for patients who did use
and did receive treatment was 1.05 (0.82, 1.35). Compared to
patients who did not use and did not receive treatment in the
prior year, the unadjusted RR for virologic suppression after an
interview for patients who did use, but did not receive treat-
ment was 0.91 (0.84, 0.99). The corresponding adjusted RRs
for virologic suppression after an interview were 1.17 (0.94,
1.45) and 0.94 (0.86, 1.03), respectively.
Table 4 provides the unadjusted and adjusted association
between alcohol/drug treatment and scheduled appointment
attendance among those who did and did not engage in at-risk
alcohol and drug use. Compared to patients who did not re-
ceive treatment but did use in the prior year, the unadjusted
RR for attending scheduled appointments after an interview
for patients who did receive treatment and did use was 0.87
(0.78, 0.97). Compared to patients who did not receive
treatment and did not use in the prior year, the unadjusted RR
for attending scheduled appointments after an interview for
patients who did receive treatment, but did not use was 0.97
(0.86, 1.09). The corresponding adjusted RRs for attending
scheduled appointments after an interview were 0.86 (0.78,
0.95) and 0.93 (0.84, 1.04), respectively.
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Table 2. Association Between At-Risk Alcohol and Drug Use and Scheduled Appointment Attendance
Among 576 African American Patients Contributing 591 Interviews by Potential Effect Measure
Modifier, Alcohol and Drug Treatment Status, UAB 1917 Clinic Cohort, 1995–2012




after interview Risk ratio 95% CLb Risk ratioc 95% CLb
Yes Yes 193/297 0.85 0.72, 0.99 0.89 0.77, 1.04
No 139/179 1. — 1. —
No Yes 786/1,048 0.94 0.90, 0.99 0.97 0.92, 1.03
No 2,078/2,606 1. — 1. —
Total 3,196/4,130
aIn the year prior to interview based on medical record and self-report at interview.
bCL, confidence limits.
cAdjusted for age, date, gender, CD4 cell count, and an AIDS diagnosis at first clinic visit as well as time since first clinic visit in addition
to CD4 cell count, time on antiretroviral therapy, education, insurance, history of mental health issues, history of mental health treatment,
and long-term history of at-risk alcohol and drug use at interview. Long-term at-risk alcohol and drug use excluded use history in the year
prior to interview.
Table 1. Characteristics of HIV-Infected African American Patients, UAB 1917 Clinic Cohort, 1995–2012
Includedb Excludedc Excludedd
Characteristica N = 591 interviews N = 185 interviews N = 166 patients
Date at first clinic visit 2010 (2008; 2011) 2008 (2007; 2011) 2009 (2008; 2010)
Date of interview 2010 (2009; 2011) 2010 (2009; 2012) —
Age at first clinic visit, years 34 (27; 44) 34 (28; 43) 40 (30; 47)
Age at interview, years 36 (28; 46) — —
Male sex, % (n) 75 (443) 74 (137) 72 (119)
Prior clinical AIDS diagnosis at first clinic visit, % (n) 33 (193) 25 (46) 38 (63)
CD4 count at first clinic visit, cells/ll 331 (147; 529) 371 (219; 538) 277 (118; 526)
CD4 count at interview, cells/ll 321 (142; 530) — —
Time on antiretroviral therapy at interview, years 0 (0; 0.88) — —
Highest education level attained at interview, % (n)
College graduate or greater 18 (104) — —
High school diploma or GED/othere 65 (383) — —
Less than high school diploma or GED 17 (104) — —
Insurance at interview, % (n)
Private 26 (155) — —
Publicf 24 (140) — —
Uninsured 50 (296) — —
History of mental health issues at interview, % (n) 64 (377) — —
History of mental health treatment at interview, % (n) 5 (31) — —
History of long-term at-risk alcohol or drug use at
interview,g % (n)
19 (115) — —
At-risk alcohol or drug use in year prior to interview, % (n) 34 (202) 42 (77) —
Alcohol or drug treatment in year prior to interview, % (n) 13 (74) 17 (31) —
Number of scheduled appointments within 2 years after an
interview
7 (4; 9) — —
Number of RNA measures taken within 2 years after an
interview
4 (2; 6) — —
Proportion of scheduled appointments attended within 2
years after an interview
0.82 (0.67; 1) — —
Proportion of HIV-1 RNA measures taken within 2 years
after an interview achieving virologic suppression
0.71 (0.33; 1) — —
aMedian (quartiles), unless noted otherwise.
b591 interviews from 576 patients included in analysis.
c185 interviews from 172 patients excluded from analysis where 27 of 172 patients included in analysis for a different interview;
interview excluded due to no information available on characteristics at interview or on outcomes in the 2 years after interview.
dNo information available on alcohol/drug use and treatment in year prior to interview due to nonresponse.
eSome college, associates degree, or training at technical school.
fMedicaid, Medicare, or temporary public maternity insurance.
gExcludes use history in the year prior to interview.
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Table 5 shows the unadjusted and adjusted association be-
tween alcohol/drug treatment and virologic suppression
among those who did and did not engage in at-risk alcohol and
drug use. Compared to patients who did not receive treatment
but did use in the prior year, the unadjusted RR for virologic
suppression after an interview for patients who did receive
treatment and did use was 1.12 (0.94, 1.33). Compared to
patients who did not receive treatment and did not use in the
prior year, the unadjusted RR for virologic suppression after an
interview for patients who did receive treatment, but did not
use was 0.97 (0.79, 1.18). The corresponding adjusted RRs for
virologic suppression after an interview were 1.07 (0.92, 1.24)
and 0.87 (0.74, 1.01), respectively.
Discussion
Among 576 new or returning AA HIV + patients enrolled
and followed for 932 person-years in the UAB 1917 Clinic
Cohort, engagement in at-risk alcohol or drug use was sizable
and on par with estimates from a largely AA HIV clinic
cohort at Johns Hopkins.31 Treatment for alcohol or drugs
was somewhat more common in our analysis compared to the
largely white Fenway Community Health Center HIV clinic
cohort.32 Attendance of scheduled appointments and viro-
logic suppression in the 2 years after an interview was largely
consistent with combined data from six academic HIV clinics
where the majority of the data were contributed by HIV + AA
patients.33
Adjusted analyses indicated that at-risk alcohol or drug use
in the prior year was negatively associated with attending
scheduled appointments in the subsequent 2 years regardless of
treatment occurrence in the prior year. However, at-risk alcohol
or drug use appeared to be negatively associated with achieving
virologic suppression solely among those not also receiving
treatment. Patients who received treatment in the prior year
appeared to be less likely to attend scheduled appointments in
the subsequent 2 years regardless of whether they used in the
prior year as well. Patients who received treatment and used
appeared to be more likely to achieve virologic suppression
compared to patients who did not receive treatment but did use.
In contrast, patients who received treatment, but did not use
were less likely to achieve virologic suppression compared to
patients who did not receive treatment and did not use.
Nonetheless, many estimates were imprecise.
Prior work, which did not explore potential effect measure
modification by alcohol and drug treatment, has shown that
use/abuse of alcohol and drugs lowers scheduled appointment
attendance as well as increases the likelihood of virologic
Table 3. Association Between At-Risk Alcohol and Drug Use and Virologic Suppression Among 576
African American Patients Contributing 591 Interviews by Potential Effect Measure Modifier, Alcohol
and Drug Treatment Status, UAB 1917 Clinic Cohort, 1995–2012
Alcohol and druga Unadjusted Adjusted
Treatment Use
Virologic suppression for HIV-1 RNA
measure taken after interview/HIV-1 RNA
measures taken after interview Risk ratio 95% CLb Risk ratioc 95% CLb
Yes Yes 92/148 1.05 0.82, 1.35 1.17 0.94, 1.45
No 67/110 1. — 1. —
No Yes 425/730 0.91 0.84, 0.99 0.94 0.86, 1.03
No 1,179/1,804 1. — 1. —
Total 1,763/2,792
aIn the year prior to interview based on medical record and self-report at interview.
bCL, confidence limits.
cAdjusted for age, date, gender, CD4 cell count, and an AIDS diagnosis at first clinic visit as well as time since first clinic visit in addition
to CD4 cell count, time on antiretroviral therapy, education, insurance, history of mental health issues, history of mental health treatment,
and long-term history of at-risk alcohol and drug use at interview. Long-term at-risk alcohol and drug use excluded use history in the year
prior to interview.
Table 4. Association Between Alcohol and Drug Treatment and Scheduled Appointment Attendance
Among 576 African American Patients Contributing 591 Interviews by Potential Effect Measure
Modifier, At-Risk Alcohol and Drug Use Status, UAB 1917 Clinic Cohort, 1995–2012




after interview Risk ratio 95% CLb Risk ratioc 95% CLb
Yes Yes 193/297 0.87 0.78, 0.97 0.86 0.78, 0.95
No 786/1,048 1. — 1. —
No Yes 139/179 0.97 0.86, 1.09 0.93 0.84, 1.04
No 2,078/2,606 1. — 1. —
Total 3,196/4,130
aIn the year prior to interview based on medical record and self-report at interview.
bCL, confidence limits.
cAdjusted for age, date, gender, CD4 cell count, and an AIDS diagnosis at first clinic visit as well as time since first clinic visit in addition
to CD4 cell count, time on antiretroviral therapy, education, insurance, history of mental health issues, history of mental health treatment,
and long-term history of at-risk alcohol and drug use at interview. Long-term at-risk alcohol and drug use excluded use history in the year
prior to interview.
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failure.4,9,12,31 The results of the current study are largely
consistent with this prior work. However, the decrease in vi-
rologic suppression associated with use was solely observed
among those patients who also did not receive treatment in the
prior year, potentially indicating that the detrimental effect of
use on virologic suppression may be more pronounced among
those who use in the absence of treatment.
The observed inverse association between alcohol/drug
treatment and scheduled appointment attendance is inconsis-
tent with prior work.20,32,34,35 Using data from the Community
Health Advisory and Information Network (CHAIN), Messeri
et al.20 showed that among HIV-infected participants reporting
a current alcohol/drug problem those who reported participat-
ing in a therapeutic or self-help alcohol or drug program were
more likely to enter as well as be retained (i.e., regularly in
contact with provider and receiving appropriate services) in
HIV medical care. However, the observed association was
significant only for self-help alcohol and drug programs.
Ashman et al.35 as well as Lo and colleagues32 similarly found
positive associations between treatment for substance abuse
and retention in care (i.e., regular contact with medical pro-
vider) while only Ashman et al. showed statistically significant
evidence of a link between receiving treatment and a higher
number of visits to a primary care medical provider.
Differences between prior work and our results may be due
to differences in the study population where prior studies
either included few or were not solely comprised of AAs. In
addition, the measure of engagement or retention in care in
prior studies was how regularly a participant received care
rather than adherence to scheduled appointments. The influ-
ence of alcohol and drug treatment on adherence to scheduled
appointments may be distinct from regular receipt of appro-
priate HIV care.33,36 Specifically, while alcohol and drug
treatment may increase receipt of regular care among those
engaged in at-risk alcohol/drug use by facilitating any clinic
attendance in a defined time interval via scheduled or walk-
in/urgent care visits, treatment may be a marker of more
severe use and in turn decrease the likelihood of appointment
adherence given the unstable lifestyle often associated with
at-risk alcohol and drug use.20 Treatment as a marker of more
severe alcohol and drug use among users is consistent with
the fact that the inverse association between use and sched-
uled appointment attendance that was observed in our study
was somewhat more pronounced among those who had re-
ceived treatment in the prior year. Among those who were
considered to be nonusers, treatment may be a marker of use
that the medical record and self-report data did not capture or
residual social and economic instability.
Among patients who used in the same period, the higher
likelihood of virologic suppression experienced by those in
treatment compared to patients not in treatment may be due to
the greater receipt and more timely modification of ARTs by
those in treatment due to more regular receipt of care despite
poorer appointment adherence. However, among patients
who did not use in the same period, the lower likelihood of
virologic suppression experienced by those in treatment
compared to patients not in treatment may be due to lower
receipt and less timely modification of as well as poorer ad-
herence to ARTs by patients in treatment. Non-at-risk alcohol
and drug users in treatment may include former users who
suffer from residual social and economic instability that
hinders ART use. Alternatively, patients we considered to be
non-at-risk alcohol and drug users in treatment may include
at-risk alcohol and drug users. Although imprecise, addi-
tional analyses among at-risk alcohol and drug users indi-
cated that those in treatment were more likely to initiate ART
at a given visit subsequent to interview than patients not in
treatment. In contrast, among non-at-risk-alcohol and drug
users, those in treatment were less likely to initiate ART
compared to patients not in treatment (results not shown).
Our results, however, contradict previous work by Smith-
Rohrberg et al.37 that showed an inverse, but imprecise asso-
ciation between referral to drug abuse services and virologic
suppression among a cohort of HIV + active drug users in New
Haven, Connecticut receiving directly administered ART.
This unexpected inverse association may have been due to the
small sample size, limited follow-up, and/or residual con-
founding bias. Furthermore, referral to drug abuse services
may not always correspond to receipt of such services.
There are limitations to the present research. The limited
sample size among those using or in treatment resulted in im-
precise estimates in many cases and also increased the chances
of random error. Although adjustment was used to correct for
measured sources of confounding and selection bias, such as
bias stemming from differences in the characteristics shown in
Table 1 between patients who were and were not included in
Table 5. Association Between Alcohol and Drug Treatment and Virologic Suppression Among 576
African American Patients Contributing 591 Interviews by Potential Effect Measure Modifier,
At-Risk Alcohol and Drug Use Status, UAB 1917 Clinic Cohort, 1995–2012
Alcohol and druga Unadjusted Adjusted
Use Treatment
Virologic suppression for HIV-1 RNA
measure taken after interview/HIV-1 RNA
measures taken after interview Risk ratio 95% CLb Risk ratioc 95% CLb
Yes Yes 92/148 1.12 0.94, 1.33 1.07 0.92, 1.24
No 425/730 1. — 1. —
No Yes 67/110 0.97 0.79, 1.18 0.87 0.74, 1.01
No 1,179/1,804 1. — 1. —
Total 1,763/2,792
aIn the year prior to interview based on medical record and self-report at interview.
bCL, confidence limits.
cAdjusted for age, date, gender, CD4 cell count, and an AIDS diagnosis at first clinic visit as well as time since first clinic visit in addition
to CD4 cell count, time on antiretroviral therapy, education, insurance, history of mental health issues, history of mental health treatment,
and long-term history of at-risk alcohol and drug use at interview. Long-term at-risk alcohol and drug use excluded use history in the year
prior to interview.
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our analysis,27–29 unmeasured potential sources of these biases
related to factors such as prison history as well as receipt of
other ancillary services (e.g., case management, transportation,
housing assistance) may exist. Residual sources of confound-
ing and selection bias may also be present due to poten-
tial measurement error of patient characteristics included in
Table 1 that were used to control for such biases.
Bias related to measurement error stemming from potential
underascertainment of at-risk alcohol and drug use or asso-
ciated treatment based on the use of UAB 1917 Clinic Cohort
medical records and self-reports may also have been present.
This measurement error is likely independent with respect to
both outcomes given that alcohol/drug use and treatment were
ascertained based on reports by the patient or information
included in the medical record by the clinician, while sched-
uled appointment attendance was ascertained from an ad-
ministrative database and virologic suppression was based on
HIV RNA assay data included in the patient medical record by
laboratory personnel. However, to the extent that measure-
ment error of patient characteristics existed, potential mea-
surement error of alcohol/drug use and treatment may have
been differential by both outcomes of interest. Such inde-
pendent, yet differential measurement error, if present, could
have biased the effect estimate away, toward, or through the
null.38 Bias can also occur in the presence of model mis-
specification, nonpositivity, or lack of consistency.39
Despite these limitations, there are several noteworthy
strengths of this study. This study is among the first to examine
the role of alcohol/drug use and treatment on scheduled ap-
pointment attendance and virologic suppression in an effort to
explain rather than solely describe observed racial disparities
in engagement in care and virologic response. Attempting to
explain rather than solely describing such disparities responds
to the need for the research community to prioritize identifi-
cation of the sources of racial health disparities.40–43 Identi-
fying the sources of racial disparities in HIV/AIDS is critical to
implementing interventions to minimize barriers to care
among AAs and in turn reduce substantial and longstanding
racial disparities in HIV disease. Although at-risk alcohol and
drug use was modestly lower and treatment was negligibly
higher among AA patients compared to white patients in the
UAB 1917 Clinic Cohort (results not shown), in other settings
AAs have been shown to be less likely than whites to complete
treatment services. This lower likelihood of completing
treatment services may indicate more persistent at-risk alcohol
and drug use among AA compared to white patients that may
contribute to racial disparities in clinic attendance.21,22 How-
ever, data on completion of treatment services by race were not
available for this analysis.
Furthermore, unlike prior work, we account for potential
effect measure modification by treatment when assessing the
influence of alcohol/drug use on attendance and virologic
response. Also important to note is that in some prior stud-
ies9,18,20,34 the measure of association used was the odds
ratio. However, when the outcome is not rare, the odds ratio is
prone to overestimate the risk ratio, which is the effect
measure of interest. In this study we directly estimate risk
ratios using modified Poisson regression.26 In addition, use of
both medical records and self-report helped to minimize
measurement error given that self-report in this setting has
been shown in previous work25 to enhance the accuracy of
medical record data alone in capturing at-risk alcohol and
drug use. Lastly, correct model specification was facilitated
by including indicator variables for categories and restricted
quadratic splines for continuous predictors.
In summary, our study found that among new or returning
to care HIV + AAs in the UAB 1917 Clinic Cohort, at-risk
alcohol/drug use in the prior year was negatively associated
with scheduled appointment attendance overall, but nega-
tively associated with virologic suppression only among
those not in treatment for alcohol/drugs. Receipt of treatment
in the prior year was also negatively associated with attend-
ing appointments yet positively associated with achieving
virologic suppression only among patients who engaged in
at-risk alcohol or drug use. Unfortunately, many of the ob-
served associations were imprecise. Therefore, future studies
should thoroughly collect relevant information on and ex-
amine the influence of alcohol/drug use and treatment on
scheduled appointment attendance and virologic response
among a larger sample of AA HIV + clinic cohort patients.
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